dermatology
MASI — Melasma Area and Severity Index
Standard quantitative melasma severity score (Kimbrough-Green 1994, modified Pandya 2011). Total 0–48 (0–24 for mMASI). Used in clinical trials and PROM monitoring.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Risperidone (Paediatric) · Atypical Antipsychotic — Autism Spectrum Disorder / Schizophrenia / Tic Disorders
- Carbamazepine (Paediatric) · Antiepileptic — Focal Seizures / Trigeminal Neuralgia / Bipolar Disorder
- Carbamazepine (Psychiatric Use) · Mood Stabiliser (Sodium Channel Blocker) — Bipolar Disorder
- Lisdexamfetamine · CNS Stimulant (Prodrug) — Schedule 2 Controlled Drug (ADHD / Binge Eating Disorder)
- Alglucosidase Alfa · Enzyme Replacement Therapy (Lysosomal Storage Disorder)
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.